FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4383876744> ?p ?o ?g. }

• W4383876744 abstract "To systematically evaluate the efficacy and safety of FDA-approved isocitrate dehydrogenase (IDH) inhibitors in the treatment of IDH-mutated acute myeloid leukemia (AML).We used R software to conduct a meta-analysis of prospective clinical trials of IDH inhibitors in the treatment of IDH-mutated AML published in PubMed, Embase, Clinical Trials, Cochrane Library and Web of Science from inception to November 15th, 2022.A total of 1109 IDH-mutated AML patients from 10 articles (11 cohorts) were included in our meta-analysis. The CR rate, ORR rate, 2-year survival (OS) rate and 2-year event-free survival (EFS) rate of newly diagnosed IDH-mutated AML (715 patients) were 47%, 65%, 45% and 29%, respectively. The CR rate, ORR rate, 2-year OS rate, median OS and median EFS of relapsed or refractory (R/R) IDH-mutated AML (394 patients) were 21%, 40%, 15%, 8.21 months and 4.73 months, respectively. Gastrointestinal adverse events were the most frequently occurring all-grade adverse events and hematologic adverse events were the most frequently occurring ≥ grade 3 adverse events.IDH inhibitor is a promising treatment for R/R AML patients with IDH mutations. For patients with newly diagnosed IDH-mutated AML, IDH inhibitors may not be optimal therapeutic agents due to low CR rates. The safety of IDH inhibitors is controllable, but physicians should always pay attention to and manage the differentiation syndrome adverse events caused by IDH inhibitors. The above conclusions need more large samples and high-quality RCTs in the future to verify." @default.
• W4383876744 created "2023-07-12" @default.
• W4383876744 creator A5020376217 @default.
• W4383876744 creator A5027835055 @default.
• W4383876744 creator A5041931692 @default.
• W4383876744 creator A5076831226 @default.
• W4383876744 creator A5082902882 @default.
• W4383876744 creator A5087725251 @default.
• W4383876744 date "2023-07-11" @default.
• W4383876744 modified "2023-10-06" @default.
• W4383876744 title "Efficacy and safety of FDA-approved IDH inhibitors in the treatment of IDH mutated acute myeloid leukemia: a systematic review and meta-analysis" @default.
• W4383876744 cites W1112683941 @default.
• W4383876744 cites W1840668697 @default.
• W4383876744 cites W1847894796 @default.
• W4383876744 cites W1905022268 @default.
• W4383876744 cites W1991775451 @default.
• W4383876744 cites W2000646853 @default.
• W4383876744 cites W2017044005 @default.
• W4383876744 cites W2023014046 @default.
• W4383876744 cites W2046657068 @default.
• W4383876744 cites W2127738065 @default.
• W4383876744 cites W2134061682 @default.
• W4383876744 cites W2137103862 @default.
• W4383876744 cites W2149913986 @default.
• W4383876744 cites W2517675534 @default.
• W4383876744 cites W2559537906 @default.
• W4383876744 cites W2592164001 @default.
• W4383876744 cites W2593230508 @default.
• W4383876744 cites W2750794123 @default.
• W4383876744 cites W2774533007 @default.
• W4383876744 cites W2787911840 @default.
• W4383876744 cites W2806682325 @default.
• W4383876744 cites W2902301444 @default.
• W4383876744 cites W2913322626 @default.
• W4383876744 cites W2917857677 @default.
• W4383876744 cites W2939577741 @default.
• W4383876744 cites W2995123606 @default.
• W4383876744 cites W2998985711 @default.
• W4383876744 cites W2999417355 @default.
• W4383876744 cites W3048827006 @default.
• W4383876744 cites W3080879632 @default.
• W4383876744 cites W3081020567 @default.
• W4383876744 cites W3092377143 @default.
• W4383876744 cites W3095552675 @default.
• W4383876744 cites W3126866891 @default.
• W4383876744 cites W3130857048 @default.
• W4383876744 cites W3164477864 @default.
• W4383876744 cites W3168098240 @default.
• W4383876744 cites W3175636756 @default.
• W4383876744 cites W3178135509 @default.
• W4383876744 cites W3205063602 @default.
• W4383876744 cites W4206683160 @default.
• W4383876744 cites W4207016957 @default.
• W4383876744 cites W4213359326 @default.
• W4383876744 cites W4224290890 @default.
• W4383876744 cites W4283073514 @default.
• W4383876744 cites W4286434227 @default.
• W4383876744 cites W4322761486 @default.
• W4383876744 cites W4379929371 @default.
• W4383876744 doi "https://doi.org/10.1186/s13148-023-01529-2" @default.
• W4383876744 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37434249" @default.
• W4383876744 hasPublicationYear "2023" @default.
• W4383876744 type Work @default.
• W4383876744 citedByCount "1" @default.
• W4383876744 crossrefType "journal-article" @default.
• W4383876744 hasAuthorship W4383876744A5020376217 @default.
• W4383876744 hasAuthorship W4383876744A5027835055 @default.
• W4383876744 hasAuthorship W4383876744A5041931692 @default.
• W4383876744 hasAuthorship W4383876744A5076831226 @default.
• W4383876744 hasAuthorship W4383876744A5082902882 @default.
• W4383876744 hasAuthorship W4383876744A5087725251 @default.
• W4383876744 hasBestOaLocation W43838767441 @default.
• W4383876744 hasConcept C104317684 @default.
• W4383876744 hasConcept C126322002 @default.
• W4383876744 hasConcept C127848430 @default.
• W4383876744 hasConcept C143998085 @default.
• W4383876744 hasConcept C181199279 @default.
• W4383876744 hasConcept C197934379 @default.
• W4383876744 hasConcept C2776478404 @default.
• W4383876744 hasConcept C2777150147 @default.
• W4383876744 hasConcept C2778729363 @default.
• W4383876744 hasConcept C501734568 @default.
• W4383876744 hasConcept C535046627 @default.
• W4383876744 hasConcept C55493867 @default.
• W4383876744 hasConcept C71924100 @default.
• W4383876744 hasConcept C86803240 @default.
• W4383876744 hasConcept C95190672 @default.
• W4383876744 hasConceptScore W4383876744C104317684 @default.
• W4383876744 hasConceptScore W4383876744C126322002 @default.
• W4383876744 hasConceptScore W4383876744C127848430 @default.
• W4383876744 hasConceptScore W4383876744C143998085 @default.
• W4383876744 hasConceptScore W4383876744C181199279 @default.
• W4383876744 hasConceptScore W4383876744C197934379 @default.
• W4383876744 hasConceptScore W4383876744C2776478404 @default.
• W4383876744 hasConceptScore W4383876744C2777150147 @default.
• W4383876744 hasConceptScore W4383876744C2778729363 @default.
• W4383876744 hasConceptScore W4383876744C501734568 @default.
• W4383876744 hasConceptScore W4383876744C535046627 @default.
• W4383876744 hasConceptScore W4383876744C55493867 @default.
• W4383876744 hasConceptScore W4383876744C71924100 @default.

• next